Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

3.9K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating AI-assisted image enhancement with physics-based synthesis of low-field MRI from high-field MRI.

Physics in medicine and biology·2026
Same author

Intracellular GRP78-Directed Delivery of Rapamycin by Biomolecular Condensates of Hydra-Elastin-like Polypeptides.

Biomacromolecules·2026
Same author

Correction: Targeting cell surface GRP78-CD44v interaction suppresses cell migration in triple-negative breast cancer cells.

Scientific reports·2026
Same author

An encyclopedia of the cord blood metabolome reveals maternal-fetal interactions and disease risk.

Cell reports. Medicine·2026
Same author

Comparison of combined anatomic and functional modeling with purely anatomic assessment in scar-dependent ventricular tachycardia.

Heart rhythm·2026
Same author

Targeting cell surface GRP78-CD44v interaction suppresses cell migration in triple-negative breast cancer cells.

Scientific reports·2025
Same journal

Hydration Effect of Glycopolymers on Lectin Recognition.

Biomacromolecules·2026
Same journal

Preparation of Permeable Polymersomes for Biomedical Applications.

Biomacromolecules·2026
Same journal

Navigating the Forest of Lignin-Derived Monomers for Polymer Synthesis.

Biomacromolecules·2026
Same journal

Degradable Cationic Polyesters with Tunable Anion-Induced Upper Critical Solution Temperature Coacervation.

Biomacromolecules·2026
Same journal

Understanding Lignin Radical Dynamics: Quenching Radicals by Solvent and Thermal Induced Mobility.

Biomacromolecules·2026
Same journal

Anomalous Diffusion of Nanoparticles in Semidilute Hyaluronic Acid Solutions.

Biomacromolecules·2026
See all related articles

Related Experiment Video

Updated: Sep 5, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

461

Hydra-Elastin-like Polypeptides Increase Rapamycin Potency When Targeting Cell Surface GRP78.

Hugo Avila1, Jingmei Yu1, Geetha Boddu1

  • 1Department of Pharmacology and Pharmaceutical Sciences, USC School of Pharmacy, Los Angeles, California 90089, United States.

Biomacromolecules
|July 5, 2022
PubMed
Summary
This summary is machine-generated.

Researchers developed a targeted drug carrier (5FA) for breast cancer therapy, enhancing rapamycin delivery and reducing side effects. This novel carrier, linked with peptides targeting GRP78, showed improved cellular uptake and mTORC1 inhibition in breast cancer models.

More Related Videos

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.6K
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K

Related Experiment Videos

Last Updated: Sep 5, 2025

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

461
A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction
05:28

A Semi-Quantitative Drug Affinity Responsive Target Stability DARTS assay for studying Rapamycin/mTOR interaction

Published on: August 27, 2019

16.6K
Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells
08:47

Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

Published on: May 1, 2020

3.2K

Area of Science:

  • Biotechnology
  • Cancer Therapeutics
  • Drug Delivery Systems

Background:

  • Rapalogues are effective breast cancer treatments but have poor solubility and dose-limiting toxicities.
  • Existing drug carriers often lack targeted delivery, limiting their efficacy and increasing side effects.

Purpose of the Study:

  • To develop a long-circulating, targeted drug carrier for enhanced breast cancer therapy.
  • To improve rapamycin delivery and efficacy by conjugating it to elastin-like polypeptides (ELPs) and targeting cell surface GRP78 (csGRP78).

Main Methods:

  • Development of a multiheaded drug carrier (5FA) using ELPs and rapamycin-binding domains.
  • Conjugation of 5FA with peptides targeting csGRP78 to create targeted carriers.
  • Characterization using light scattering and mass spectrometry.
  • In vitro evaluation in BT474 breast cancer cells, including cellular uptake (flow cytometry), proteolysis susceptibility (SubA), and mTORC1 inhibition (Western blot for pS6K).
  • Visualization of carrier localization using super-resolution confocal laser scanning microscopy.

Main Results:

  • Targeted carriers demonstrated enhanced cellular uptake and susceptibility to csGRP78-specific proteolysis (SubA).
  • The best carrier, L-5FA, reduced mTOR activity by 3-fold compared to non-targeted carriers or free rapamycin.
  • Targeting increased carrier exposure by approximately 8-fold, as visualized by microscopy.

Conclusions:

  • Peptide ligands for GRP78 can be effectively incorporated into protein-based drug carriers to enhance targeted delivery in breast cancer.
  • This approach offers a promising strategy to overcome the limitations of solubility and side effects associated with rapamycin therapy.